Thor Medical ASA Cash Flow Conversion Efficiency
Thor Medical ASA cash flow conversion efficiency. Based on the latest financial reports, Thor Medical ASA (TRMED) has a cash flow conversion efficiency ratio of -0.104x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-47.54 Million ≈ $-5.00 Million USD) by net assets (Nkr456.00 Million ≈ $47.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Thor Medical ASA (2020–2025)
Cash flow conversion efficiency of Thor Medical ASA from 2020 to 2025. This chart illustrates how Thor Medical ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TRMED live share price for real-time trading data and today's change.
Thor Medical ASA Cash Flow Conversion Ratio Explained
Thor Medical ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Thor Medical ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Thor Medical ASA ranked by their cash flow conversion efficiency. Also see Thor Medical ASA (TRMED) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Falcon Oil & Gas Ltd
F:FAC
|
-0.012x |
|
Waterco Ltd
AU:WAT
|
0.044x |
|
1RT Acquisition Corp.
NASDAQ:ONCH
|
-0.001x |
|
Evgo Inc
NASDAQ:EVGO
|
-0.021x |
|
Onward Medical N.V.
BR:ONWD
|
-0.366x |
|
Astral Resources NL
AU:AAR
|
-0.011x |
|
Tukas Gida Sanayi ve Ticaret AS
IS:TUKAS
|
0.109x |
|
Brightcom Group Limited
NSE:BCG
|
0.003x |
Annual Cash Flow Conversion Efficiency for Thor Medical ASA (2020–2025)
The table below shows the annual cash flow conversion efficiency of Thor Medical ASA from 2020 to 2025. Review TRMED financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr456.00 Million ≈ $47.98 Million |
Nkr-47.54 Million ≈ $-5.00 Million |
-0.104x | -48.29% |
| 2024-12-31 | Nkr337.10 Million ≈ $35.47 Million |
Nkr-23.70 Million ≈ $-2.49 Million |
-0.070x | +70.17% |
| 2023-12-31 | Nkr271.93 Million ≈ $28.61 Million |
Nkr-64.09 Million ≈ $-6.74 Million |
-0.236x | +96.32% |
| 2022-12-31 | Nkr63.84 Million ≈ $6.72 Million |
Nkr-409.08 Million ≈ $-43.05 Million |
-6.408x | -123.17% |
| 2021-12-31 | Nkr140.52 Million ≈ $14.79 Million |
Nkr-403.46 Million ≈ $-42.46 Million |
-2.871x | -28.83% |
| 2020-12-31 | Nkr178.67 Million ≈ $18.80 Million |
Nkr-398.21 Million ≈ $-41.90 Million |
-2.229x | -- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.